Biomarkers to detect and characterise cancer
AssigneeAgency for Science, Technology and Research
InventorsFrederic Bard, Zhi Hui Joanne Chia
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of detecting the presence or absence of cancer. Also disclosed herein are methods of characterising a sample from a subject thought to be suffering cancer, as well as methods of determining the malignancy, grade, or staging of a cancer. Also disclosed herein are kits utilising the methods disclosed herein.
Claims17
A method of detecting the presence or absence of cancer,
- wherein the method comprises the steps of:
- (i) obtaining a sample from a subject;
- (ii) detecting a level of O-glycosylation of one or more endoplasmic reticulum (ER)-resident proteins in the sample obtained in step (i);
- (iii) comparing the level of O-glycosylation of one or more endoplasmic reticulum (ER)-resident proteins in step (ii) with a level of O-glycosylation of one or more endoplasmic reticulum (ER)-resident proteins in a control group;
- wherein an increase in the level of O-glycosylation of one or more endoplasmic reticulum (ER)-resident proteins present in the sample compared to the control group is indicative of the presence of cancer.
A method of determining the risk of a subject developing cancer, wherein the method comprises the steps of:
- (i) obtaining a sample from a subject;
- (ii) detecting a level of O-glycosylation of one or more endoplasmic reticulum (ER)-resident proteins in the sample;
- (iii) comparing the level of O-glycosylation of one or more endoplasmic reticulum (ER)-resident proteins in step (ii) with a level of O-glycosylation of one or more endoplasmic reticulum (ER)-resident proteins in a control group;
- wherein an at least 4-fold increase in the level of O-glycosylation of one or more endoplasmic reticulum (ER)-resident proteins present in the sample compared to the control group is indicative that the subject is suffering from cancer.
A method of determining the malignancy, grade, or staging of a cancer, the method comprising
- (i) obtaining a sample from a subject;
- (ii) detecting a level of O-glycosylation of one or more endoplasmic reticulum (ER)-resident proteins in the sample;
- (iii) comparing the level of O-glycosylation of one or more endoplasmic reticulum (ER)-resident proteins in step (ii) with a level of O-glycosylation of one or more endoplasmic reticulum (ER)-resident proteins in a group defined for each grade of cancer.
A kit comprising:
- (i) a monosaccharide-binding protein capable of binding to one or more O-glycosylated endoplasmic reticulum (ER)-resident proteins;
- (ii) a detection agent capable of binding to the monosaccharide-binding protein and/or the one or more O-glycosylated endoplasmic reticulum (ER)-resident proteins;
- and
- (iii) one or more standards, wherein each standard comprises an O-glycosylated endoplasmic reticulum (ER)-resident protein selected from the group consisting of protein disulfide isomerase family A member 4 (PDIA4), calnexin (CANX), protein disulfide isomerase family A member 3 (PDIA3), Endoplasmic Reticulum Lectin 1 (ERLEC1), and heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5/GRP78/Bip).
Dependencies are inferred from the claim text.